| Business Summary | | Elite
Pharmaceuticals,
Inc.
(EPI)
is
the
holding
company
of
Elite
Laboratories,
Inc.
(ELI),
which
primarily
is
engaged
in
researching,
developing,
licensing,
manufacturing,
and
marketing
proprietary
drug
delivery
systems
and
products.
ELI
has
concentrated
on
developing
orally
administered
controlled
release
products.
EPI
has
undertaken
and
completed
several
contract
product
development
projects
for
clients,
including
Celgene,
Novo
Nordisk
and
SmithKline
Beecham.
The
Company
has
developed
products
incorporating
cardiovasculars,
anti-inflammatory
agents,
antidiabetic,
cough
and
cold
preparations,
bronchodilators,
analgesics,
and
anti-infectives.
The
Company's
products
include
Nifelite
(Nifedipine),
Diltilite
CD
(Diltiazem),
Diltilite
SR,
Ketolite
CR
(Ketoprofen),
Verelite
CR
(Verapamil),
Glucolite
CR
(Glipizide),
and
Diclofelite
CR
(Diclofenac).
Several
of
these
oral
controlled
release
products
are
available
for
license
worldwide. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ELI
engages
in
researching,
developing,
licensing,
manufacturing,
and
marketing
proprietary
drug
delivery
systems
and
products.
Elite
also
conducts
research
and
development
projects
sponsored
by
other
pharmaceutical
companies.
For
the
three
months
ended
6/30/01,
revenues
totaled
$76
thousand,
up
from
$0.
Net
loss
fell
24%
to
$447
thousand.
Results
reflect
a
$76
thousand
product
formulation
fee,
partially
offset
by
a
$61
thousand
equity
loss
in
joint
venture. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2001 Pay | |
| Atul Mehta, Ph.D., 52 Pres,
CEO, Director | $297K | Mark Gittelman, 41 Sec.,
Treasurer | -- | Dollar amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|